Applied BioCode (6598) — Capital Reinvestment Ratio

Latest as of September 2022: 1.89x

Applied BioCode (6598) has a Capital Reinvestment Ratio of 1.89x as of September 2022, meaning it reinvests 2% of its operating cash flow (NT$6.35 Million) in capital expenditures (NT$12.00 Million). Check Applied BioCode (6598) tangible net worth to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

1.89x
Capex / Operating Cash Flow

Operating Cash Flow

NT$6.35 Million
TWD

Capital Expenditures

NT$12.00 Million
TWD

Data as of

Sep 2022
Most recent filing

Applied BioCode Capital Reinvestment Ratio (2022–2022)

This chart tracks Applied BioCode's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see 6598 cash flow conversion.

Annual Capital Reinvestment Ratio for Applied BioCode (2022–2022)

Year-by-year Capital Reinvestment Ratio for Applied BioCode from 2022 to 2022. See free cash flow generation of Applied BioCode to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2022 0.15x NT$145.87 Million NT$22.14 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow